Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Trevi Therapeutics Inc (TRVI)

Trevi Therapeutics Inc (TRVI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 129,211
  • Shares Outstanding, K 38,686
  • Annual Sales, $ 0 K
  • Annual Income, $ -33,940 K
  • 60-Month Beta 0.18
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 10.80
Trade TRVI with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.21
  • Number of Estimates 2
  • High Estimate -0.19
  • Low Estimate -0.23
  • Prior Year -0.49
  • Growth Rate Est. (year over year) +57.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.91 +95.29%
on 06/23/22
3.86 -3.37%
on 07/06/22
+1.25 (+50.40%)
since 06/06/22
3-Month
1.91 +95.29%
on 06/23/22
3.86 -3.37%
on 07/06/22
+1.83 (+96.32%)
since 04/06/22
52-Week
0.46 +710.87%
on 02/23/22
3.86 -3.37%
on 07/06/22
+1.55 (+71.10%)
since 07/06/21

Most Recent Stories

More News
5 Best Performing Micro-Cap Stocks Through the First Half of 2022

The first half of 2022 is finally in the books and it could not have come sooner. Major U.S. indices

^BTCUSD : 20,291.40 (-0.79%)
^BTCUSDT : 20,270.15 (-0.68%)
FEDU : 14.46 (-4.87%)
NERV : 3.21 (-1.23%)
TRVI : 3.73 (+11.68%)
NVCT : 13.00 (unch)
HUSA : 3.93 (-0.76%)
Wall Street Predicts These 2 Sub-$5 Stocks Have More Than 200% Upside

Concerns over the Federal Reserve’s aggressive interest rate hikes to fight elevated inflation and the possibility of the economy tipping into a recession have fostered significant volatility in the...

PRVB : 3.99 (unch)
TRVI : 3.73 (+11.68%)
Trevi Therapeutics Reports Positive Results from the Ph2b/3 PRISM Trial of Haduvio™ in the Treatment of Prurigo Nodularis

/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral...

TRVI : 3.73 (+11.68%)
These 2 Penny Stocks Have Over 300% Upside on the Horizon, Says Oppenheimer

Earlier this month, the S&P 500 officially entered a bear market; its current year-to-date loss stands at 21%, and the NASDAQ, which has fallen faster and farther, stands at a 30% ytd loss. The rapid reversal...

PRVB : 3.99 (unch)
TRVI : 3.73 (+11.68%)
Merck (MRK) Q1 Earnings & Sales Beat, COVID Drug Adds $3.3B

Merck (MRK) beats Q1 estimates for earnings and sales. The company anticipates robust growth in revenues and income to continue in 2022.

AZN : 66.49 (+1.50%)
MRK : 93.13 (+0.53%)
VYGR : 6.18 (-3.74%)
TRVI : 3.73 (+11.68%)
Sanofi (SNY) Q1 Earnings Top, Vaccines Recover, CHC Sales Rise

Sanofi (SNY) beats first-quarter estimates for earnings and sales. Dupixent drives sales growth along with strong recovery in travel vaccines. Consumer healthcare sales remain strong.

REGN : 594.90 (-0.28%)
SNY : 50.04 (-0.28%)
VYGR : 6.18 (-3.74%)
TRVI : 3.73 (+11.68%)
Axsome (AXSM) Surges on Potential Approval for AXS-05 Soon

The FDA provides post-marketing requirements/commitments related to Axsome's (AXSM) under-review NDA for its lead pipeline candidate, AXS-05, for treating MDD. Investors anticipate an approval shortly....

JAZZ : 160.44 (+0.25%)
AXSM : 42.74 (+3.71%)
TRVI : 3.73 (+11.68%)
AXLA : 2.03 (-2.40%)
KemPharm (KMPH) Starts Early-Stage Cardiovascular Safety Study

KemPharm (KMPH) initiates dosing in a phase I study to evaluate the cardiovascular safety profile of its lead pipeline candidate, KP1077's sole active API, serdexmethylphenidate.

NVS : 83.73 (-0.65%)
KMPH : 4.58 (-1.93%)
VYGR : 6.18 (-3.74%)
TRVI : 3.73 (+11.68%)
TG Therapeutics (TGTX) Withdraws FDA Submission, Stock Down

TG Therapeutics (TGTX) voluntarily withdraws regulatory application seeking approval for the combination regimen, ublituximab plus Ukoniq. It also withdraws Ukoniq from sale in approved indications.

TGTX : 5.29 (+0.76%)
VYGR : 6.18 (-3.74%)
TRVI : 3.73 (+11.68%)
AXLA : 2.03 (-2.40%)
Are You Looking for a Top Momentum Pick? Why Trevi Therapeutics, Inc. (TRVI) is a Great Choice

Does Trevi Therapeutics, Inc. (TRVI) have what it takes to be a top stock pick for momentum investors? Let's find out.

TRVI : 3.73 (+11.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in...

See More

Key Turning Points

3rd Resistance Point 4.17
2nd Resistance Point 3.81
1st Resistance Point 3.57
Last Price 3.73
1st Support Level 2.97
2nd Support Level 2.61
3rd Support Level 2.37

See More

52-Week High 3.86
Last Price 3.73
Fibonacci 61.8% 2.56
Fibonacci 50% 2.16
Fibonacci 38.2% 1.76
52-Week Low 0.46

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar